Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 17.77 USD -2.2% Market Closed
Market Cap: 900.4m USD

During the last 3 months Theravance Biopharma Inc insiders have not bought any shares, and sold 1.3m USD worth of shares. The stock price has increased by 28% over this period (open performance analysis).

The last transaction was made on Dec 3, 2025 by Farnum Rhonda , who sold 145.6k USD worth of TBPH shares.

Last Transactions:
Farnum Rhonda
$-145.6k
Broshy Eran
$-280k
Broshy Eran
$-545.8k
Broshy Eran
$-286.8k
Farnum Rhonda
$-7.8k
Farnum Rhonda
$-264k
Farnum Rhonda
$-36k
Farnum Rhonda
$-36k
Farnum Rhonda
$-36k
Samaha Eli
$+7.8m
Farnum Rhonda
$-36k
Samaha Eli
$+8.7m
Farnum Rhonda
$-10.9k
Farnum Rhonda
$-14.2k
Graham Richard A
$-25.4k
Graham Richard A
$-22.4k
Graham Richard A
$-24.5k
Farnum Rhonda
$-17.1k
Graham Richard A
$-23.2k
Graham Richard A
$-22.8k
Graham Richard A
$-24.8k
Farnum Rhonda
$-19.9k
Graham Richard A
$-26.1k
Graham Richard A
$-27.6k
Graham Richard A
$-24k
Farnum Rhonda
$-40.8k
Graham Richard A
$-23.3k
Winningham Rick E
$-559.5k
Graham Richard A
$-22.4k
Hindman Andrew A.
$-716.2k
Graham Richard A
$-47.6k
Graham Richard A
$-132.6k
View All Transactions

During the last 3 months Theravance Biopharma Inc insiders have not bought any shares, and sold 1.3m USD worth of shares. The stock price has increased by 28% over this period (open performance analysis).

The last transaction was made on Dec 3, 2025 by Farnum Rhonda , who sold 145.6k USD worth of TBPH shares.

Sold
0-3
months
1.3m USD
2
3-6
months
7.8k USD
1
6-9
months
300k USD
1
9-12
months
36k USD
1
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Theravance Biopharma Inc
Insider Trading Chart

Theravance Biopharma Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Theravance Biopharma Inc
Last Insider Transactions

Global
Insiders Monitor

Theravance Biopharma Inc
Glance View

Market Cap
900.4m USD
Industry
Pharmaceuticals

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

TBPH Intrinsic Value
13.81 USD
Overvaluation 22%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top